EU Stands Firm Against Big Pharma's Lobbying Efforts
TL;DR
The European Union has confirmed a new measure that will remove two years of data protection from all new medicines launched in the EU, allowing unbranded rivals to enter the market more quickly. The reform aims to tackle the uneven rollout of drugs across the EU and includes incentives for pharmaceutical companies that launch their medicines in all EU 27 countries. The regulation and directive will have to go through the EU's legislative process before being approved, and it's unlikely this will be done before European Parliament elections in 2024.
Topics:worldhealthcare#drug-regulation#drug-shortages#environmental-monitoring#eu#healthcare#pharmaceutical-industry
- Big Pharma meets its match as EU refuses to budge POLITICO Europe
- EU publishes proposed drug laws overhaul, seting up tussle with industry Reuters
- EU to unveil reforms for cheaper drugs Deccan Herald
- Will the Commission blink under pressure from pharma? We’re about to find out POLITICO Europe
- GSK says EU pharma legislation overhaul could trigger investment shift Reuters
Want the full story? Read the original reporting
Read on POLITICO Europe